期刊
RESVERATROL AND HEALTH
卷 1290, 期 -, 页码 59-66出版社
BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.12145
关键词
resveratrol; phytoestrogen; osteogenesis; osteoporosis; menopause
资金
- European Commission Framework 7 program (EUFP7) [HEALTH.2012.2.4.5-2, 305815]
- Arthritis Research U.K.
- Medical Research Council
There are a number of pharmacological agents for the treatment of bone mineral loss and osteoporosis. Hormone replacement therapy (HRT) with estrogen is an established treatment, but it has several adverse side effects and can increase the risk of cancer, heart disease, and stroke. There is increasing interest in nutritional factors and naturally occurring phytochemical compounds with the potential for preventing age-related and postmenopausal bone loss. Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a polyphenolic phytoestrogen with osteogenic and osteoinductive properties. It can modify the metabolism of bone cells and has the capacity to modulate bone turnover. This paper provides an overview of current research on resveratrol and its effects on bone cells in vitro, highlighting the challenges and opportunities facing this area of research, especially in the context of providing nutritional support for postmenopausal women who may not benefit from HRT and older patients with various forms of arthritis, metabolic bone disease, and osteoporosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据